What a 1 mL syringe does that a 0.3 mL syringe does not
The graduation interval differs between barrel sizes, and a 1 mL barrel is frequently marked in two-unit steps. Reading one as though it were marked in single units halves…
Dosing
Page 25 of 31 of this archive, newest first.
The incretin receptors, ranked by how much we actually know about them
The receptor is expressed in more tissues than the popular account allows, and that is the whole story.
Randomised withdrawal is the cleanest design in this field and the least discussed
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A year after stopping: what the trials found at the far end
The physiology of regain was described a decade before these drugs, and it explains the trajectory without invoking anything specific to them.
Seasonal use, holiday use, and the honest state of the evidence
An absence of evidence is not evidence of harm. It is also not a licence.
What the tirzepatide schedule assumes about a person it has never met
We work the arithmetic out in full, because it is arithmetic and it is short.
What the new Singapore guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Canada pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
Brazil pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The intramuscular injection nobody intended
The insulin injection-technique literature is large, well conducted and directly transferable on questions of depth and tissue. We say where it stops transferring.
The convention nobody explains before handing over the vial
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
Why people actually stop, in the order they actually stop
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
The mechanism behind the mechanism
What scintigraphy and breath-test studies established about emptying rate, and what they did not.
Why your endoscopist wants to know about your injection
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
Escalating onto a rising curve
What the published pharmacokinetics permit, what the labels state, and where the two diverge.